Compare Neurocrine Biosciences Inc (NBIX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Revvity Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Revvity Inc trades at $110.1 (market cap $11.87B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Revvity Inc pays a 0.26% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RVTY | |
|---|---|---|
Market Cap | $17.40B | $11.87B |
Sector | Health | Technology |
52-Week High | $180.55 | $117.75 |
52-Week Low | $123.10 | $82.26 |
Enterprise Value | $16.49B | $14.36B |
Dividend Yield | — | 0.26% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
